← All trials
NCT05909631
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2023
- Primary completion
- Feb 20, 2023
- Completion date
- Apr 11, 2023
- First posted
- Jun 18, 2023
- Last posted
- Jun 18, 2023
- Enrollment
- 180
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sulaimany Polytechnic universityLead sponsor
- Sulaimany Polytechnic universityReponsible party - principal investigator
- Sulaimany Polytechnic universitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.